Twitter | Pretraživanje | |
Krystal Biotech
Krystal Biotech, Inc. is using gene therapy to develop effective and novel treatments for skin diseases.
70
Tweetovi
107
Pratim
178
Osobe koje vas prate
Tweetovi
Krystal Biotech 27. sij
We broke ground on a second cGMP facility for our treatments for skin conditions. The Astra facility is intended to support potential commercial production of B-VEC, formerly KB103, as well as ongoing R&D efforts. Full details here:
Reply Retweet Označi sa "sviđa mi se"
Krystal Biotech 23. sij
We are pleased to announce the strengthening of our team with Jennifer Chien joining the newly created CCO position. Ms. Chien brings more than 20 years commercial leadership experience that is critical as we look towards potential launch of KB103 in 2021:
Reply Retweet Označi sa "sviđa mi se"
Krystal Biotech 28. stu
Today's article from and highlights as one of 11 companies leading the way by making early investments in manufacturing, greatly streamlining the therapy development process. Read it here:
Reply Retweet Označi sa "sviđa mi se"
Krystal Biotech 26. stu
CEO Krish S. Krishnan will be presenting a corporate update at the upcoming Piper Jaffray 31st Annual Healthcare Conference in New York on Tuesday December 3 at 9:10 a.m. ET. Webcast link for the presentation can be found here:
Reply Retweet Označi sa "sviđa mi se"
Krystal Biotech 5. stu
We published a corporate update and third quarter 2019 financial results. Click here to see the full release: and check for additional info.
Reply Retweet Označi sa "sviđa mi se"
Krystal Biotech 29. lis
In the final data update from the Phase 1/2 trial of KB103, now B-VEC, the topical induced rapid and durable wound closure in patients with dystrophic and was safe and well-tolerated. Read the full release here:
Reply Retweet Označi sa "sviđa mi se"
Krystal Biotech 16. lis
We reinforced our IP portfolio with (1) a US patent for our platform technology, and (2) the first foreign patent (Australia) for our lead product KB103. We remain committed to developing novel therapeutics for rare skin diseases. Full release
Reply Retweet Označi sa "sviđa mi se"
Krystal Biotech 10. lis
The EMA Committee for Orphan Medicinal Products issued a positive opinion on our orphan designation application for KB105, our second treatment, for patients with transglutaminase-1 deficient autosomal recessive congenital ichthyosis:
Reply Retweet Označi sa "sviđa mi se"
Krystal Biotech 9. ruj
A new was just initiated and will study topical KB105 for treatment of transglutaminase-1 (TGM1) deficient autosomal recessive congenital (ARCI). Read more about the trial here:
Reply Retweet Označi sa "sviđa mi se"
Krystal Biotech 3. ruj
CEO Krish Krishnan shares his advice with on raising capital in and on how previous success in the industry paved the way for an initially self-funded company and a rapid IPO. Read the full story here:
Reply Retweet Označi sa "sviđa mi se"
Krystal Biotech 20. kol
KB103 study coordinator Dr. Peter Marinkovich was featured in speaking about trial results, future plans and the hope this developmental could give to all those affected by dystrophic . Read it here:
Reply Retweet Označi sa "sviđa mi se"
Krystal Biotech 5. kol
Krystal reports second quarter 2019 financial results including recent milestones and program updates. Full release here:
Reply Retweet Označi sa "sviđa mi se"
Krystal Biotech 24. lip
Data from the Phase 2 GEM2 study show that KB103 was well-tolerated and induced rapid & durable wound closure in adult & pediatric patients with dystrophic . Granted RMAT designation paves way for a planned pivotal Phase 3 before 2020.
Reply Retweet Označi sa "sviđa mi se"
Krystal Biotech 14. lip
We submitted an IND for a new candidate, KB105, for patients with the TGM-1 deficient autosomal recessive congenital ichthyosis (“ARCI”). Read the full release here:
Reply Retweet Označi sa "sviđa mi se"
Krystal Biotech 29. ožu
KB103, our clinical-stage first-in-class topical for the treatment of dystrophic , was granted PRIME eligibility by , allowing for frequent and early interactions with the EMA to accelerate development:
Reply Retweet Označi sa "sviđa mi se"
Krystal Biotech proslijedio/la je tweet
debra of America 25. ožu
. is currently recruiting patients onto their Phase 2 Study of KB103 (The GEM Study). KB103 is a topical gene therapy being evaluated in RDEB patients. For more information, please visit:
Reply Retweet Označi sa "sviđa mi se"
Krystal Biotech 7. ožu
We celebrated the opening of Ancoris, our GMP facility for all production needs for KB103, our developmental treatment for dystrophic . We were honored to be joined by :
Reply Retweet Označi sa "sviđa mi se"
Krystal Biotech 4. ožu
Join us in welcoming the newest member of our Board of Directors, Julian S Gangolli, whose vast experience with product launches will be invaluable as we progress our lead developmental product KB103 towards commercialization. For more details, see here:
Reply Retweet Označi sa "sviđa mi se"
Krystal Biotech 12. velj
A new article from highlights Ancoris, our state-of-the-art GMP facility designed to meet expected current and future research and production needs for lead developmental KB103, for . Read the story here:
Reply Retweet Označi sa "sviđa mi se"
Krystal Biotech 16. sij 2019.
Our new state-of-the-art GMP facility, Ancoris, set to be the primary production site to meet projected research and commercial demand for KB103, was just completed. We're already planning a second facility to meet all future needs. Full news release here:
Reply Retweet Označi sa "sviđa mi se"